AERIE PHARMACEUTICALS, INC.
FORT WORTH, TX

Aerie Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Fort Worth, Texas, with its mailing address at 6201 South Freeway, Fort Worth, TX 76134, US. Incorporated on September 28, 2017, under the status of Florida.Models.Dos.FloridaCompanyStatus and filed as number F17000004386 in DE, Aerie Pharmaceuticals specializes in ophthalmic solutions to treat glaucoma, ocular hypertension, diabetic macular edema (DME), and wet age-related macular degeneration (AMD). The company's main product candidates include Rhopressa® and Roclatan™, both of which have been rigorously evaluated through clinical trials. Their innovation focuses on Rho kinase inhibitors, aimed at modulating ocular conditions by impacting fibrosis in the trabecular meshwork and promoting nutrient delivery to diseased tissues. Aerie Pharmaceuticals commenced its Mercury 3 trial for European market approval in mid-2017 to compare Roclatan™ with Ganfort®, a similar product marketed in Europe. This trial is pivotal in enhancing their commercialization prospects abroad. Additionally, they are exploring extended applications of Rho kinase inhibitors through ongoing preclinical studies. Notable compounds include AR-13503, targeting both Rho kinase and protein kinase C to significantly reduce lesion size in animal models for AMD and DME, and AR-1105, a prospective treatment for DME derived from a dexamethasone steroid. Aerie Pharmaceuticals owns worldwide rights to their products with robust intellectual property protections expected to last at least until 2030. The company intends to self-commercialize its products in North America while considering partnerships or independent commercialization strategies in Europe and Japan, contingent on successful product development outcomes. Key milestones continue to unfold as the company expands both its market presence and research portfolio. Interested parties can contact the Board of Directors for inquiries via their official communications channel listed at aeriepharmaceuticals.com. The company's leadership includes President David J Endicott, along with notable representatives eannette Bankes J and Ian Bell, who oversee strategic directions and operational excellence in research and development.